Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049329 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL15096036 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL9575627 | 0.80 | MAPT (0.47) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL5611799 | 0.80 | MAPT (0.46) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL25455136 | 0.80 | KDM4E (0.46) | ALDH1A1MAPTCA12CA1CA9 | |
| 1,4-Diallyloxybenzene SCHEMBL302448 | 0.79 | CA12 (0.63) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL8935650 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL7929787 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL8419864 | 0.78 | FFAR1 (0.46) | ALDH1A1MAPTPOLBUSP2CACNA1B | |
| SCHEMBL826483 | 0.78 | CA12 (0.53) | ALDH1A1MAPTPOLBUSP2CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148299-A1 | FEM1B PROTEIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-20230148299-A1 | FEM1B PROTEIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-7524882-B2 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1539136-B1 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2008-07-09 | — | — | EP | disclosed |
| EP-1539136-A4 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1539136-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004010936-A2 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230148299-A1 | FEM1B PROTEIN BINDING AGENTS AND USES THEREOF | FEM1B, GSKIP, FNIP1 | ALDH1A1 4563/4885MAPT 2106/4885POLB 1422/4885 |
| US-20050228044-A1 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | PPARD, PPARA, PPARG | ALDH1A1 426/4885MAPT 4125/4885POLB 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.